GSK still a top pick in pharma sector for Deutsche Bank

Group 1 - Deutsche Bank has upgraded GSK's price target to 1,850p from 1,700p, indicating a positive outlook for the company [1] - GSK is ranked as a top pick in the pharmaceutical sector, alongside Novo and Novartis, while AstraZeneca, Roche, and Sanofi are considered less favorable options [1] - Berenberg predicts a strong finish for GSK in 2023, supported by the performance of its RSV vaccine Arexy [1] Group 2 - GSK announced the acquisition of Aiolos Bio for up to US$1.4 billion, which may enhance its portfolio and growth prospects [1] - GSK's shares eased slightly to 1,568p following the news [1]